Schroder Investment Management Group Vaxcyte, Inc. Transaction History
Schroder Investment Management Group
- $101 Billion
- Q4 2024
A detailed history of Schroder Investment Management Group transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Schroder Investment Management Group holds 44,818 shares of PCVX stock, worth $3.74 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,818
Previous 14,374
211.8%
Holding current value
$3.74 Million
Previous $1.64 Million
123.52%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PCVX
# of Institutions
346Shares Held
130MCall Options Held
534KPut Options Held
248K-
Vanguard Group Inc Valley Forge, PA12MShares$997 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$882 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$829 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$724 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$518 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.94B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...